Sidoti Starts Cyberonics (CYBX) at Buy But Stock Selling-Off
More News related to CYBX
- Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference
- Piper Jaffray Upgrades Cyberonics, Inc. (CYBX) to Overweight
- After-Hours Movers 11/18: DCI, CYBX, LTD Higher; JACK, NMM, AFFY, HOTT, SMTC, MVIS Lower
- Cyberonics (CYBX) Posts Q2 adj.-EPS of $0.32, Tops Street; Boosts FY10 Revenue Guidance
- Cyberonics Reports Record Sales and Operating Profit in Fiscal 2010 Second Quarter
Sidoti & Co. initiates coverage on Cyberonics (Nasdaq: CYBX) with a Buy rating and a $22 price target.
Despite the bullish research note, shares of Cyberonics are moving slightly lower today. The stock most recenlyt traded at $16.50, down about 1.8% from yesterday's closing price.
Cyberonics, Inc., a neuromodulation company, engages in the design, development, manufacture, sale, and marketing of implantable medical devices that provide vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy and treatment-resistant depression.
Related Categories
New CoverageStocks Mentioned
+1.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
